Clinical trial

The Effect of Intravenous Lidocaine Infusion on Hemodynamic Reaction to Tracheal Intubation, as Well as Metabolic and Hormonal Response to Laparoscopic Procedure in Children: a Randomized Controlled Trial

Name
Lido02
Description
Intravenous lidocaine - a potent local anesthetic with analgesic and anti- inflammatory properties has been shown to be an effective adjunct that reduces intra and postoperative opioid consumption and facilitates pain management in adults. In children population promising but limited evidence is available. The study has been planned to evaluate the efficacy of continuous intravenous infusion of lidocaine in alleviation of hemodynamic reaction to tracheal intubation, as well as metabolic and hormonal response to laparoscopic procedure in children.
Trial arms
Trial start
2022-03-12
Estimated PCD
2023-08-08
Trial end
2023-08-08
Status
Completed
Phase
Early phase I
Treatment
Intravenous lidocaine
Intraoperative intravenous lidocaine infusion.
Arms:
Lidocaine
Other names:
IVL
Normal saline infusion
Intraoperative intravenous normal saline infusion.
Arms:
Control
Other names:
Placebo
Size
132
Primary endpoint
Hemodynamic reaction to tracheal intubation
Before intubation - immediately after intubation.
Eligibility criteria
Inclusion Criteria: * ASA physical status class 1E, 2E, 3E; * Patients undergoing laparoscopic appendectomy. Exclusion Criteria: * Allergy to local anesthetics or contraindications for the use of lidocaine; * ASA physical status class 4E or higher; * Severe cardiovascular disease; * Preoperative bradycardia; * Preoperative atrioventricular block; * Renal failure; * Chronic treatment with analgesics; * Legal guardians' refusal.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'SUPPORTIVE_CARE', 'maskingInfo': {'masking': 'QUADRUPLE', 'maskingDescription': 'The drug or placebo(normal saline) will be placed in a syringe by the principal investigator. Only principal investigator will be aware of the participants allocation. The principal investigator will not be involved in the process of: recruitment, providing an intervention, or outcomes assessment.', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 132, 'type': 'ACTUAL'}}
Updated at
2023-10-31

1 organization

2 products

5 indications

Product
Lidocaine
Indication
Appendicitis